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Abstract: A rapid diagnosis of drug-resistant tuberculosis (TB) is critical for early initiation of effective
therapy. Molecular testing with line probe assays (MTBDRplus and MTBDRsl) on culture isolates
has been available for some time and significantly reduces the time to diagnosis of drug resistance.
However, routine use of this test directly on sputum is less common. As part of enrollment screening
procedures for tuberculosis clinical trials conducted in Hanoi, Vietnam, we evaluated the feasibility
and performance of line probe assay (LPA) testing directly on sputum samples from 315 participants
with no prior history of TB treatment. Test performance characteristics for the detection of rifampin
(RIF) and isoniazid (INH) drug resistance as compared to culture-based drug susceptibility testing
(DST) reference standard were calculated. LPA demonstrated high sensitivity and specificity for the
diagnosis of drug resistance. Scaling up molecular testing on sputum as part of time-sensitive clinical
trial screening procedures in high TB burden settings is feasible and will reduce both time to initiation
of appropriate therapy and the risk of late exclusions due to microbiologic ineligibility.
Keywords: MTBDRplus; MTBDRsl; line probe assay; tuberculosis; DR-TB; Hain test; diagnostics;
clinical trials; molecular testing
1. Introduction
Tuberculosis (TB) remains a public health threat with an estimated 10 million people diagnosed
and 1.3 million deaths worldwide in 2017 alone [1]. The global prevalence of drug-resistant tuberculosis
(DR-TB) is increasing, yet only 25% of those newly infected with TB in 2017 were enrolled in
treatment [1]. In response, the latest report by the World Health Organization highlights improvement
in TB diagnostics and shortening the time to initiation of appropriate treatment as key priorities [1].
Furthermore, the recent guidelines recommend drug sensitivity testing in all settings, shifting the
paradigm of TB treatment from standardized regimens to individualized therapy [2]. The identification
of drug resistance by culture-based methods takes 8–12 weeks, delaying identification of individuals
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with DR-TB by several months. Though rapid molecular tests have been developed to identify DR-TB,
questions surrounding their feasibility has limited their use in high TB burden settings. Moreover, the
GeneXpert MTB/RIF assay, the most commonly accessible rapid molecular assay in the field, currently
only tests for resistance to rifampin. In many program settings, additional information on isoniazid
and fluoroquinolone resistance can be informative in selecting the appropriate combination regimen
for the patient. In the context of clinical trial screenings, rapid detection of resistance to rifampin,
isoniazid, and fluoroquinolones is essential for identifying eligible study participants. Rapid screening
can prevent treating participants with drugs to which their bacteria have resistance, expedites access to
curative therapy, and reduces risks for late exclusions, which impact the integrity of the clinical trial.
Molecular testing of culture isolates for drug resistance using commercial line probe assays (Hain
Genotype®, Hain Lifesciences, Germany) has been extensively reported. In Vietnam, sensitivity of 93.1%
for rifampin (RIF) resistance, 92.6% for isoniazid (INH) resistance, and 88.9% for multidrug-resistant TB
(MDR-TB) have been reported with 100% specificity [3]. Although less commonly used, MTBDRplus
tested directly on sputum samples has demonstrated acceptable test performance characteristics
compared to culture when used on smear-positive sputum samples in several settings [4–7].
Nevertheless, molecular testing on sputum is not routinely conducted. Current practice across
clinical trials networks and sites varies in terms of screening procedures and the use of rapid diagnostic
testing for the detection of drug resistance. Three recent phase 3 trials for drug-sensitive TB (DS-TB)
reported 6–12% of those enrolled as late exclusions due to drug resistance [8–10]. We sought to assess
the feasibility and test characteristics of using line probe assay (LPA) testing directly on sputum as part
of the screening for TB clinical trial enrollment in Hanoi, Vietnam.
2. Materials and Methods
This cross-sectional study was conducted during a screening of 394 participants for enrollment
into CDC-TB Trials Consortium Study 29X (S29X) and Study 31 (S31), conducted in Hanoi, Vietnam,
between February 2012 and October 2018. S29X (ClinicalTrials.gov Identifier: NCT00694629) and S31
(ClinicalTrials.gov Identifier: NCT02410772) were phase 2 and phase 3 clinical trials, respectively, each
evaluating rifapentine (RPT)-based regimens for the treatment for DS-TB [11]. A clinical research nurse
coordinator conducted standard enrollment procedures (informed consent, interview, chest X-ray,
laboratory testing, sputum culture (Lowenstein–Jensen, LJ), and drug susceptibility testing (DST))
for all participants. In addition, the Genotype MTBDRplus VER 2.0 and MTBDRsl VER 2.0 assays
(Hain Lifescience GmbH, Nehren, Germany) were performed directly on sputum specimens within
24–48 h of collection. MTBDRplus was used to detect resistance to rifampin (mutations in the rpoB
gene) and isoniazid (katG and inhA genes), and MTBDRsl (Hain Lifescience GmbH, Nehren, Germany)
was used to detect fluoroquinolones (gyrA gene) resistance. We followed the manufacturer’s directions
to perform the assays. Results of resistance identified through molecular testing initiated a return
evaluation, prerandomization exclusion from enrollment, and referral to the Vietnam National TB
Programme (NTP) for further management of drug-resistant TB.
We calculated the sensitivity, specificity, positive predictive value (PPV), and negative predictive
value (NPV) of line probe assay (LPA) using results of drug susceptibility testing (DST) on
Lowenstein–Jensen (LJ) medium and the BACTEC Mycobacterial Growth Indicator Tube (MGIT;
Becton Dickinson and Co., Franklin Lakes, NJ, USA) liquid medium with the MGIT 960 system as
the reference standards. Drug-resistant TB (DR-TB) was defined as TB resistant to any of the first-line
TB treatment agents. Multidrug-resistant TB (MDR-TB) was defined as TB resistant to isoniazid and
rifampin. Statistical analysis was conducted using Excel (Microsoft, Redmond, WA, USA) and Stata 13
(StataCorp, College Station, TX, USA).
3. Results
A total of 394 participants were screened for enrollment in S29X and S31. Of these, 79 participants
were excluded from analyses because of missing reference culture-based DST results, missing LPA
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results, indeterminate LPA results, negative culture for mycobacterium TB, or negative smears. Three
hundred fifteen smear-positive participants with complete phenotypic and molecular assay results
were included in the quantitative analysis. The study cohort had a median age of 40 years (range
17–79) and was 80% male. At the time of presentation, 74% of the participants had cavitary lesions on
chest radiographs. The median sputum mycobacterial load was 2+ (interquartile range 1).
Phenotypic DST demonstrated 76 cases of INH monoresistance (24%), three cases of RIF
monoresistance (0.9%), and MDR-TB in ten participants (3.2%). LPA identified 76/86 participants
with INH-resistant TB (including MDR-TB) by phenotypic DST (sensitivity 88%, 95% Confidence
Interval (CI) 80–94%) and was positive for INH resistance in six participants with INH-susceptible
TB by phenotypic DST (specificity 97%, 95% CI 94–99%) (Table 1). 86% of participants identified by
LPA with INH resistance harbored isolates with katG mutations. LPA identified 9/13 participants with
rifampin-resistant TB (sensitivity 69%, 95% CI 39–91%) and 301/302 patients with rifampin-susceptible
TB (specificity 100%, 95% CI 97–100%). LPA also identified 5/6 patients with ofloxacin-resistant TB
(sensitivity 83%, 95% CI 36–100%) and 183/188 patients with ofloxacin-sensitive TB (specificity 97%, 95%
CI 94–99%). LPA results were available to clinicians within a median of 31 h (interquartile range 25 h),
enabling all 80 (27%) participants with positive molecular results for INH resistance to be excluded
from the clinical trial prior to randomization and to be referred for initiation of appropriate therapies
from the Vietnam NTP. The median time to treatment initiation in our study from the time of sputum
collection was two days (interquartile range 2 days).
Table 1. Performance of MTBDRplus testing on sputum samples compared with culture-based drug
susceptibility testing (DST) results. INH = isoniazid. MDR-TB = multidrug-resistant TB. NPV =
negative predictive value. OFX = ofloxacin/moxifloxacin. PPV = positive predictive value. RIF
= rifampin.
INH RIF OFX MDR-TB
% 95% CI % 95% CI % 95% CI % 95% CI
Sensitivity 88 80–94 69 39–91 83 36–100 80 44–97
Specificity 97 94–99 100 98–100 97 94–99 100 98–100
PPV 93 85–97 90 55–100 50 19–81 89 52–100
NPV 96 92–98 99 97–100 99 97–100 99 98–100
4. Discussion
Our experience in applying the Hain LPA directly on sputum for diagnosis of drug-resistant
tuberculosis in Hanoi, Vietnam, supports its feasibility as a component of the screening process for
TB clinical trials. Diagnostic performance characteristics for LPA in our context were similar to those
reported in nontrial settings on direct sputum, with a sensitivity of 88% and a specificity of 97% for the
detection of INH resistance. Sensitivity for RIF resistance was 69%, lower than reported elsewhere [6,7],
and might be due to the low prevalence of RIF resistance in our study (only 13 patients), the existence
of alternative mutations conferring rifampicin resistance than identified by LPA testing, or possible
coexisting drug-resistant and drug-susceptible strains or heteroresistance [12].
The use of molecular testing as a screening tool enabled us to exclude one-third of the screened
participants who would have otherwise been potentially randomized and enrolled into the trials,
which consequently would have resulted in them receiving treatments to which their isolates were
not fully susceptible. Of note, all screened participants reported no prior history of tuberculosis
treatment, and the local epidemiology of drug resistance in different settings would impact the added
value of routinely integrating rapid molecular testing for participants screened for clinical trials. The
prevalence of INH resistance in our study population was 27%, which was higher than the 16–20%
prevalence previously reported in programmatic data from Vietnam [13]. Early detection of drug
resistance in DR-TB endemic settings such as ours could have a significant impact on the number of
participants excluded from clinical trials due to microbiological ineligibility, making studies more
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efficient and less costly, as well as assuring with greater certainty that patients infected with isolates
with drug resistance are initiated on appropriate therapies. Indeed, early detection of INH resistance
by MTBDRplus enabled all 82 participants with INH resistance identified by MTBDRplus (including
nine participants with MDR-TB) to be promptly referred to the Vietnam NTP for treatment initiation
using appropriate drug regimens. In light of rising rates of drug resistance globally and the risks
of acquisition of additional resistance when inappropriate regimens are used, scaling up molecular
testing on sputum would allow for more timely initiation of effective therapy. Indeed, the feasibility of
rapid molecular testing on sputum samples has been associated with a median decrease in time of
25–66 days to appropriate treatment initiation in some programmatic settings [14,15]. Rapid molecular
testing diagnostic algorithms have also been shown to correspond to as much as 4.5 times reduction in
healthcare cost per patient when compared to phenotypic DST [16].
Our study has several limitations. Our experience applies to Hanoi, Vietnam, and the performance
characteristics of LPA testing may differ in other clinical trial contexts with higher or lower endemic
levels of drug resistance. Although LPA testing in our study provided a result within 36 h after the
screening visit, requiring close collaboration between field and laboratory personnel, this might not
be possible in all settings where infrastructure and expertise for line probe assay testing are limited.
Nonetheless, our results underscore the feasibility of this approach to rapid molecular testing for drug
resistance that could be applied in programmatic settings that have the appropriate support as our
clinical trial unit which is embedded in the Vietnam NTP.
Early and rapid detection of drug resistance in the clinical trial setting has several potential
benefits such as improved efficiency, cost, and patient care that will allow trials to perform in keeping
with good clinical practices. In addition, the use of molecular drug susceptibility testing in clinical
trials will reduce the risk of late exclusions due to microbiologic ineligibility. Routine adoption of
molecular assays applied directly to sputum for the detection of drug resistance is an effective means of
improving current TB clinical trials practice. Beyond the clinical trial setting, the scale-up of molecular
testing on sputum will assure that the appropriate therapy is initiated for patients with drug resistance
and that TB treatment outcomes are improved.
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